Vol 7, No 3 (2022)
Original article
Published online: 2022-08-09

open access

Page views 3882
Article views/downloads 323
Get Citation

Connect on Social Media

Connect on Social Media

Evaluation of the associations between GDF-15, OPG, and IL-15 levels in CRC: preliminary results

Julia Robotycka1, Sylwia Mielcarska1, Miriam Dawidowicz1, Agnieszka Kula1, Błażej Ochman1, Tomasz Niebudek1, Bogumiła Strzałkowska1, Dariusz Waniczek2, Elżbieta Świętochowska1
Medical Research Journal 2022;7(3):208-214.


Introduction: Osteoprotegerin (OPG), Interleukin-15 (IL-15), and Growth/Differentiation Factor-15 (GDF-15) are all proven to take part in the processes associated with colorectal carcinoma (CRC) including tissue remodeling, inflammation modulation, and metastasis. Aim of the study: To investigate the concentrations of GDF-15, OPG and IL-15 in tumor and margin tissues of CRC in relation to clinicopathological features of patients.

Material and methods: The study used 50 specimens of tumor and tumor-free margin tissues obtained from CRC patients. To determine the GDF-15, OPG and IL-15 concentrations commercially available enzyme-linked immunosorbent assay (ELISA) kits were used.

Results: Concentrations of GDF-15, OPG and IL-15 were significantly higher in the tumor in comparison with the margin. The tumor levels of GDF-15 were positively associated with those of OPG and IL-15, while tumor levels of OPG correlated positively with those of IL-15. There was no association between levels of investigated molecules and clinical features of patients.

Conclusions: The levels of GDF-15, OPG and IL-15 are elevated in patients suffering from CRC. More studies are needed to establish a specific role of these cytokines in the development, tumor growth, progression, and prognosis of CRC and to examine their role as possible CRC treatment candidates.

Article available in PDF format

View PDF Download PDF file


  1. Xi Y, Xu P. Global colorectal cancer burden in 2020 and projections to 2040. Transl Oncol. 2021; 14(10): 101174.
  2. Johnson CM, Wei C, Ensor JE, et al. Meta-analyses of colorectal cancer risk factors. Cancer Causes Control. 2013; 24(6): 1207–1222.
  3. Amersi F, Agustin M, Ko CY. Colorectal cancer: epidemiology, risk factors, and health services. Clin Colon Rectal Surg. 2005; 18(3): 133–140.
  4. Sammarco G, Gallo G, Vescio G, et al. Mast cells, microRNAs and others: the role of translational research on colorectal cancer in the forthcoming era of precision medicine. J Clin Med. 2020; 9(9).
  5. Keum N, Giovannucci E. Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies. Nat Rev Gastroenterol Hepatol. 2019; 16(12): 713–732.
  6. Hsiao EC, Koniaris LG, Zimmers-Koniaris T, et al. Characterization of growth-differentiation factor 15, a transforming growth factor beta superfamily member induced following liver injury. Mol Cell Biol. 2000; 20(10): 3742–3751.
  7. Li C, Wang X, Casal I, et al. Growth differentiation factor 15 is a promising diagnostic and prognostic biomarker in colorectal cancer. J Cell Mol Med. 2016; 20(8): 1420–1426.
  8. Bondurant KL, Lundgreen A, Herrick JS, et al. Interleukin genes and associations with colon and rectal cancer risk and overall survival. Int J Cancer. 2013; 132(4): 905–915.
  9. Tsuruda T. Osteoprotegerin: osteo-vascular connection. J Atheroscler Thromb. 2015; 22(3): 233–234.
  10. Rochette L, Meloux A, Rigal E, et al. The role of osteoprotegerin and its ligands in vascular function. Int J Mol Sci. 2019; 20(3).
  11. Tsukamoto S, Ishikawa T, Iida S, et al. Clinical significance of osteoprotegerin expression in human colorectal cancer. Clin Cancer Res. 2011; 17(8): 2444–2450.
  12. Guo J, Liang Y, Xue D, et al. Tumor-conditional IL-15 pro-cytokine reactivates anti-tumor immunity with limited toxicity. Cell Res. 2021; 31(11): 1190–1198.
  13. Wang Y, Jiang T, Jiang M, et al. Appraising growth differentiation factor 15 as a promising biomarker in digestive system tumors: a meta-analysis. BMC Cancer. 2019; 19(1): 177.
  14. Holen I, Shipman CM. Role of osteoprotegerin (OPG) in cancer. Clin Sci (Lond). 2006; 110(3): 279–291.
  15. McGonigle JS, Giachelli CM, Scatena M. Osteoprotegerin and RANKL differentially regulate angiogenesis and endothelial cell function. Angiogenesis. 2009; 12(1): 35–46.
  16. Cross SS, Yang Z, Brown NJ, et al. Osteoprotegerin (OPG) - a potential new role in the regulation of endothelial cell phenotype and tumour angiogenesis? Int J Cancer. 2006; 118(8): 1901–1908.
  17. Kim HS, Yoon G, Do SI, et al. Down-regulation of osteoprotegerin expression as a novel biomarker for colorectal carcinoma. Oncotarget. 2016; 7(12): 15187–15199.
  18. Pettersen I, Bakkelund W, Smedsrød B. Osteoprotegerin is expressed in colon carcinoma cells. Anticancer Res. 2005; 25(6B): 3809–3816.
  19. Liu X, Li Y, Sun X, et al. Powerful anti-colon cancer effect of modified nanoparticle-mediated IL-15 immunogene therapy through activation of the host immune system. Theranostics. 2018; 8(13): 3490–3503.
  20. Geerts D, Chopra C, Connelly L. Osteoprotegerin: relationship to breast cancer risk and prognosis. Front Oncol. 2020; 10: 462.
  21. De Toni EN, Nagel D, Philipp AB, et al. Correlation between baseline osteoprotegerin serum levels and prognosis of advanced-stage colorectal cancer patients. Cell Physiol Biochem. 2018; 45(2): 605–613.
  22. Rocca YS, Roberti MP, Juliá EP, et al. Phenotypic and functional dysregulated blood NK cells in colorectal cancer patients can be activated by cetuximab plus il-2 or IL-15. Front Immunol. 2016; 7: 413.
  23. Bahri R, Pateras IS, D'Orlando O, et al. IL-15 suppresses colitis-associated colon carcinogenesis by inducing antitumor immunity. Oncoimmunology. 2015; 4(9): e1002721.
  24. Wallin U, Glimelius B, Jirström K, et al. Growth differentiation factor 15: a prognostic marker for recurrence in colorectal cancer. Br J Cancer. 2011; 104(10): 1619–1627.
  25. Vocka M, Langer D, Fryba V, et al. Growth/differentiation factor 15 (GDF-15) as new potential serum marker in patients with metastatic colorectal cancer. Cancer Biomark. 2018; 21(4): 869–874.
  26. Li C, Wang J, Kong J, et al. GDF15 promotes EMT and metastasis in colorectal cancer. Oncotarget. 2016; 7(1): 860–872.